Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"Phase II Study to Evaluate the Activity and Safety of Cabozantinib in Pretreated, Advanced RET-rearranged Non-small Cell Lung Cancer Patients: CRETA Trial"

NCT04131543 is registered in ClinicalTrials.gov with University of Bologna as lead sponsor.

NCT NCT04131543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04131543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"Phase II Study to Evaluate the Activity and Safety of Cabozantinib in Pretreated, Advanced RET-rearranged Non-small Cell Lung Cancer Patients: CRETA Trial"
Lead sponsor
University of Bologna
Phase
Phase 2
Overall status
Unknown status
Start date
August 7, 2019
Completion date
August 7, 2022
Enrollment
25 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer